References
- Mungall BA, Hoet B, Nieto Guevara J, et al. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Rev Vaccines. 2022;21(2):201–214.
- Greenberg D, Hoover PA, Vesikari T, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine. 2018;36(45):6883–6891.
- Platt HL, Greenberg D, Tapiero B, et al., V114-008 Study Group. A phase II trial of safety, tolerability and immunogenicity of V114, a 15-Valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in healthy infants. Pediatr Infect Dis J. 2020 Aug;39(8):763–770. PMID: 32639460; PMCID: PMC7360095.
- Lupinacci R, Rupp R, Wittawatmongkol, et al. A phase 3, multicenter, randomized double-blind, active-comparator controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114 in healthy infants (Pneu-PED). 12th World Congress of the World Society for Pediatric Infectious Diseases (Virtual). 2022 Feb 22 – 24. WSPID2022 Congress Abstracts Book: WSPID2022 Abstracts Book.
- Vaxneuvance. U.S. Food and Drug Administration (Silver Spring, MD: U.S. Food and Drug Administration). https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxneuvance Accessed 22 July 2022